Thymosin Alpha-1 is a thymic immune-signaling peptide studied in viral infection, hepatitis, and sepsis — here is what the research actually shows.

The short version

Here's Thymosin Alpha-1 in plain English: it's a tiny peptide — a string of 28 amino-acid building blocks — that your thymus (a small immune-training gland behind your breastbone) makes naturally. Its job is to help tune the immune system. It nudges immune cells to mature and talk to each other, so the body can both fight infections better and avoid overreacting. Scientists made an exact synthetic copy of it called thymalfasin (a generic drug name), and they have studied it for decades in liver infections (hepatitis), blood infections (sepsis), COVID-19, and cancer.

The honest state of the evidence: in chronic viral hepatitis the signal is fairly steady, but in sepsis the largest, most careful trial found no benefit at all. It is generally easy to tolerate — the main complaint is a sore spot where the shot goes in. It is not FDA-approved in the United States, though it is sold in roughly 35 other countries. What people report — including the downsides — is on Thymosin Alpha-1 effects.

What the Thymosin Alpha-1 research has shown

Thymosin Alpha-1 (often written Tα1, and made as the synthetic drug thymalfasin) is an immunomodulator — a molecule that adjusts, rather than simply boosts, how the immune system behaves ^[4]. It was first pulled out of calf thymus tissue and sequenced by Allan Goldstein and colleagues in 1977, who established it as a 28-amino-acid chain with an acetyl cap on one end (a small chemical tag that turns out to be essential for the peptide to work) ^[1].

In the body it doesn't act on muscle, growth, or performance — it acts on immune cells. It signals through pattern-recognition receptors called Toll-like receptors (sensors that immune cells use to spot trouble), especially TLR2 and TLR9, on dendritic cells — the immune system's scouts that show captured threats to other cells ^[5][9]. That wakes up the broader T-cell response and can also reverse T-cell exhaustion (a worn-out state immune cells fall into during long or severe infections) ^[6]. The full mechanism is on thymosin alpha 1 mechanism of action.

The headline numbers

The clearest way to read this compound is by the studies that put numbers on it.

In severe COVID-19, a retrospective review of 76 patients reported markedly lower mortality with Tα1 treatment — 11.11% versus 30.00% (P=0.044) — alongside a measurable rise in blood T-cell numbers and a reversal of T-cell exhaustion markers (PD-1 and Tim-3) on CD8+ cells ^[6]. In severe sepsis, the earlier ETASS trial of 361 patients saw 28-day mortality of 26.0% versus 35.0%, a roughly 9-point drop that hovered right at the edge of statistical significance ^[2].

Then the big one landed. The phase-3 TESTS trial — 1,106 adults with sepsis across 22 centres, double-blind and placebo-controlled — found no significant difference in 28-day mortality: 23.4% versus 24.1%, hazard ratio 0.99 (P=0.93) ^[3]. That null result is the most important caveat on this whole page, and it sits right at the top of every page here on purpose.

Not the same molecule

Thymosin Alpha-1 gets confused with a handful of other thymic peptides constantly. It is worth getting this straight up front, because they are genuinely different molecules:

• Thymosin beta-4 (TB-500) is a different peptide — 43 amino acids, binds the cell-skeleton protein actin, and is the one on the WADA prohibited list. Tα1 is 28 amino acids and is an immune signaller, not an actin binder.
• Thymulin (FTS) is a tiny zinc-dependent nonapeptide (nine amino acids).
• Thymopentin (TP-5) is a five-amino-acid fragment.
• Thymalin is a separate preparation — a bovine thymic extract, not a single defined peptide and not a brand of Tα1.
• Prothymosin alpha is the larger 113-amino-acid precursor that Tα1 is cut out of inside the body.

The full side-by-side, with sequence, size, mechanism, and use, lives on the thymosin alpha 1 mechanism of action page.

Where to read next

This site is organized so you can go as deep as you want. The Thymosin Alpha-1 research page walks through the mechanism and the key trials with heavy citation. The Thymosin Alpha-1 effects page covers what people actually report — benefits and downsides, clearly labeled — plus the cited safety cautions. The dosage page summarizes the doses, routes, and durations studied in trials (never a recommendation), and the Thymosin Alpha-1 references page lists every source with its DOI or PubMed link. Two dedicated deep-dives cover thymosin alpha 1 covid and the molecule's mechanism. Nothing here is dosed, sold, or prescribed — it's an editorial read of the literature.